Finance

Beta
Lists
TRVI:NASDAQ
Trevi Therapeutics Inc
$18.15
+0.83%
(+0.15) 1D
$18.15
0.00% (0.00)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRVI...
Open
$17.92
High
$18.32
Low
$17.62
Mkt. cap
2.58B
Avg. vol.
1.58M
Volume
6.90M
52-wk high
$18.32
52-wk low
$5.41
EPS
-$0.32
Beta
1.04
Shares outstanding
141.98M
No. of employees
34
Open
$17.92
High
$18.32
Low
$17.62
Mkt. cap
2.58B
Avg. vol.
1.58M
Volume
6.90M
52-wk high
$18.32
52-wk low
$5.41
EPS
-$0.32
Beta
1.04
Shares outstanding
141.98M
No. of employees
34
News stories
From sources across the web
About Trevi Therapeutics Inc
CEO-
Employees34
Founded2011
HeadquartersNew Haven, Connecticut, United States
SectorPharmaceutical industry
Websitetrevitherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to TRVI in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TRVI in the last 3 months.
Highest
Current $18.15
$30.00 (+65.29%)
Average
$24.43 (+34.60%)
Lowest
$20.00 (+10.19%)
Analyst
Recommendation
Action
Price target
Projected
Date
Serge Belanger
Needham
Buy
Maintained
$23.00
+26.7%
05/20/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$24.00
+32.2%
05/08/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$29.00
+59.8%
05/07/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$24.00
+32.2%
05/06/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$30.00
+65.3%
05/08/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$21.00
+15.7%
05/08/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$20.00
+10.2%
05/05/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$25.00
+37.7%
03/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.39M
10.08M
6.19M
9.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.33M
3.83M
4.03M
4.97M
Operating expense
13.72M
13.92M
10.22M
14.91M
Total operating expenses
13.72M
13.92M
10.22M
14.91M
Operating income
-13.72M
-13.92M
-10.22M
-14.91M
Other non operating income
-7.00K
-2.00K
-15.00K
-
EBT including unusual items
-12.32M
-11.82M
-8.33M
-13.21M
EBT excluding unusual items
-12.32M
-11.82M
-8.33M
-13.21M
Income tax expense
-21.00K
-15.00K
-16.00K
-20.00K
Effective tax rate
0.17%
0.13%
0.19%
0.15%
Other operating expenses
-
-
-
-
Net income
-12.30M
-11.80M
-8.32M
-13.19M
Net profit margin
-
-
-
-
Earnings per share
-0.09
-0.08
-0.06
-0.09
Interest and investment income
1.41M
2.10M
1.90M
1.70M
Interest expense
-
-
-
-
Net interest expenses
1.41M
2.10M
1.90M
1.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.68M
-13.88M
-10.19M
-14.88M
Gain or loss from assets sale
-
-
7.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of TRVI
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer